No Data
No Data
Buy Rating Affirmed for Alumis Inc. on Strong Prospects for TYK2 Inhibitor ESK-001
Alumis Shares Are Trading Higher. The Company Announced It Initiated Onward Phase 3 Clinical Program for ESK-001.
Top Premarket Gainers
Express News | Alumis Initiates ONWARD Phase 3 Clinical Program For ESK-001 In Moderate-To-Severe Plaque Psoriasis; Co-Primary Endpoint PASI 75 And SPGA 0/1 At 24 Weeks To Support U.S. Regulatory Submission; Topline Data Expected In 2026
Express News | Alumis: Topline Data Anticipated in 2026
Express News | Alumis: Initiates Onward Phase 3 Clinical Program Evaluating Esk-001, an Oral Tyk2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
No Data